



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

KY-1044

Cat. No.:	HY-P99431
CAS No.:	2489390-15-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	<p>KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS^{high} cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcγRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8⁺ T_{Eff} cells (through FcγR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response^[1].</p>								
In Vitro	<p>KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 hours) causes human natural killer (NK) cells expressing hICOS (5:1 effector:target cell ratio) to induce potent ADCC-mediated killing (EC₅₀=5.6 pmol/L)^[1].</p> <p>KY-1044 significantly induces the luciferase signal (EC₅₀ of 0.15 nmol/L). A similar EC₅₀ is obtained against mouse ICOS (0.53 nmol/L), rat ICOS (0.48 nmol/L), or cynomolgus monkey ICOS (0.22 nmol/L)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; ip; twice a week for 3 weeks) mIgG2a (effector enable) monotherapy blocks tumor growth in lymphoma/myeloma tumor models^[1].</p> <p>In syngeneic mouse tumor models, KY-1044 depletes ICOS^{high} Treg and increases the intratumoral T_{Eff}:Treg ratio, resulting in increased secretion of IFNγ and TNFα by T_{Eff} cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>200 μg (10 mg/kg)</td> </tr> <tr> <td>Administration:</td> <td>IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation</td> </tr> <tr> <td>Result:</td> <td>Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).</td> </tr> </table>	Animal Model:	8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells ^[1]	Dosage:	200 μg (10 mg/kg)	Administration:	IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation	Result:	Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).
Animal Model:	8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells ^[1]								
Dosage:	200 μg (10 mg/kg)								
Administration:	IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation								
Result:	Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).								

REFERENCES

[1]. Richard C.A. Sainson, et al. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer Immunol Res. 2020 Dec;8(12):1568-1582.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA